Home  >  TopNews
you can get e-magazine links on WhatsApp.Click here
Pioma_Lactic
Corporate + Font Resize -

Venus Remedies continues to address unmet medical needs through R&D

Yash Ved, Mumbai
Tuesday, September 14, 2021, 08:00 Hrs  [IST]

Venus Remedies Ltd, one of India’s leading research-driven pharmaceutical companies, has stated that it will continue to focus on research and development (R&D) as one of its key growth enablers to address unmet medical needs.

Elaborating on the company’s thrust on research, Saransh Chaudhary, CEO, Venus Medicine Research Centre (VMRC), and president, critical care division, Venus Remedies, said, “We will continue to nurture intellectual property wealth by consistently working towards developing novel products, particularly in the antimicrobial resistance segment. We recognise this imminent threat and have been working in this area for over a decade now.”

The company said that it is also drawing on latest state-of-the-art technologies backed by cutting-edge research spearheaded by the VMRC to come up with disruptive products in the consumer healthcare segment.

Venus Remedies, which recently launched its full-fledged consumer healthcare division by introducing a novel nanotechnology-based herbal pain management solution, is planning to come up with similar over-the-counter research products in the next five years, covering the crucial gastroenterology, hygiene, pain management, stress management and vitamins and supplements segments.

With the world gripped by the Covid crisis, the company has also risen to the occasion by catering to the requirements of Covid patients through medicines like enoxaparin, which addresses the problem of blood coagulation.

Venus Remedies’ flagship antibiotic research product, Elores, has already helped millions of patients, but bacteria are becoming increasingly resistant to most last-line antibiotics. So as to significantly improve the quality of care available for critical care patients dealing with life-threatening bacterial infections, particularly in ICU settings, the VMRC is developing a platform technology called Renal Guard.

This platform technology aims to significantly reduce the nephrotoxicity associated with the use of polymyxin antibiotics, which are currently the last line of defence in the fight against drug-resistant infections.

“On the pharmaceutical R&D side, we will be looking to commercialise our anti-infective R&D pipeline products, particularly the ones being developed as part of the Renal Guard program,” said Chaudhary.

Among the other launches of Venus Remedies’ Consumer Healthcare Division is Sterloc, a hypochlorous acid (HOCl)-based natural disinfectant which is emerging as the first line of defence in the fight against Covid-19 owing to its efficacy in sanitising public places, offices and even hospitals and quarantine facilities where the viral load is much higher.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |